Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 1/20 | 0.48 |
| ▸ | OPRD1 | P41143 | 7/20 | 0.47 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.47 |
| ▸ | NPY1R | P25929 | 1/20 | 0.46 |
| ▸ | NPY2R | P49146 | 1/20 | 0.46 |
| ▸ | NPY4R | P50391 | 1/20 | 0.46 |
| ▸ | MMP2 | P08253 | 1/20 | 0.42 |
| ▸ | ACE | P12821 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31222363 | 0.88 | NPY4R (0.58) | NPY1RNPY2RNPY4R | |
| SCHEMBL31222367 | 0.88 | FOLH1 (0.51) | FOLH1OPRD1OPRM1NPY1RNPY2R | |
| SCHEMBL31222371 | 0.88 | FOLH1 (0.51) | FOLH1OPRD1OPRM1NPY1RNPY2R | |
| SCHEMBL31222361 | 0.84 | NPY4R (0.64) | NPY1RNPY2RNPY4R | |
| SCHEMBL31222372 | 0.84 | NPY4R (0.64) | NPY1RNPY2RNPY4R | |
| SCHEMBL11136648 | 0.84 | OPRD1 (0.62) | OPRD1OPRM1 | |
| SCHEMBL1371080 | 0.83 | OPRD1 (0.48) | OPRD1OPRM1NPY1RNPY2RNPY4R | |
| SCHEMBL31222368 | 0.81 | NPY4R (0.62) | NPY1RNPY2RNPY4R | |
| SCHEMBL31222391 | 0.80 | NPY4R (0.61) | NPY1RNPY2RNPY4R | |
| SCHEMBL31222418 | 0.80 | NPY4R (0.61) | NPY1RNPY2RNPY4R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240301023-A1 | PEPTIDES AND USES THEREOF | PreveCeutical Medical Inc. (CA) | 2024-09-12 | — | — | US | claimed |
| US-20240301023-A1 | PEPTIDES AND USES THEREOF | PreveCeutical Medical Inc. (CA) | 2024-09-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240301023-A1 | PEPTIDES AND USES THEREOF | OPRL1, OPRK1, OPRM1 | FOLH1 573/4885OPRD1 4/4885OPRM1 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.